Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share News
  5. LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

Pin to quick picksGlaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

Tue, 16th Jan 2024 09:14

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

----------

FTSE 100

----------

JPMorgan cuts Rightmove to 'underweight' (neutral) - price target 493 (585) pence

----------

Goldman Sachs raises Rightmove price target to 667 (659) pence - 'neutral'

----------

JPMorgan cuts HSBC price target to 660 (690) pence - 'neutral'

----------

JPMorgan cuts Standard Chartered price target to 820 (990) pence - 'overweight'

----------

Jefferies cuts Standard Chartered price target to 1,050 (1,100) pence - 'buy'

----------

JPMorgan cuts NatWest price target to 260 (280) pence - 'overweight'

----------

JPMorgan cuts Barclays price target to 180 (190) pence - 'overweight'

----------

Jefferies raises Berkeley price target to 4,706 (4,572) pence - 'hold'

----------

Jefferies raises Barratt Developments price target to 583 (470) pence - 'hold'

----------

Peel Hunt cuts Taylor Wimpey to 'hold' (add) - price target 145 (125) pence

----------

Jefferies raises Taylor Wimpey price target to 172 (143) pence - 'buy'

----------

JPMorgan raises Taylor Wimpey price target to 101 (96) pence - 'neutral'

----------

Citigroup raises Beazley price target to 723 (680) pence - 'buy'

----------

Citigroup cuts Prudential price target to 1130 (1350) pence - 'buy'

----------

UBS cuts Rentokil Initial price target to 375 (460) pence - 'sell'

----------

Goldman Sachs raises Auto Trader group price target to 886 (863) pence - 'buy'

----------

Barclays cuts Croda International target to 5,000 (6,300) pence - 'equal weight'

----------

Goldman Sachs raises WPP price target to 870 (849) pence - 'neutral'

----------

Goldman Sachs raises Informa price target to 1,027 (1,019) pence - 'buy'

----------

Goldman Sachs raises Relx price target to 3,795 (3,405) pence - 'buy'

----------

Goldman Sachs raises Pearson price target to 1,319 (1,225) pence - 'buy'

----------

Berenberg cuts Rolls-Royce to 'sell' (hold) - price target 240 (100) pence

----------

Bernstein raises Convatec price target to 305 (285) pence - 'outperform'

----------

Morgan Stanley raises AstraZeneca price target to 13,400 (12,900) pence - 'overweight'

----------

UBS cuts AstraZeneca to 'sell' (buy) - price target 10,700 (13,000) pence

----------

Morgan Stanley raises GSK price target to 1730 (1535) pence - 'equal-weight'

----------

UBS raises GSK to 'buy' (sell) - price target 1,860 (1,310) pence

----------

Citigroup raises St James's Place price target to 667 (660) pence - 'neutral'

----------

Citigroup raises Phoenix price target to 509 (501) pence - 'neutral'

----------

Citigroup raises M&G price target to 223 (208) pence - 'neutral'

----------

Citigroup raises Legal & General price target to 254 (232) pence - 'neutral'

----------

Citigroup raises Aviva price target to 450 (422) pence - 'neutral'

----------

Deutsche Bank cuts Diageo price target to 2,450 (2,470) pence - 'sell'

----------

Goldman Sachs raises Experian price target to 4,250 (4,000) pence - 'buy'

----------

FTSE 250

----------

RBC starts Premier Foods with 'outperform' - price target 180 pence

----------

Citigroup raises Hiscox price target to 1,084 (1,032) pence - 'neutral'

----------

RBC cuts PageGroup price target to 550 (560) pence - 'outperform'

----------

Barclays raises Spire Healthcare price target to 315 (305) pence - 'overweight'

----------

Berenberg raises Direct Line to 'buy' (hold) - price target 195 (170) pence

----------

Jefferies raises Redrow price target to 774 (635) pence - 'buy'

----------

Jefferies raises Vistry price target to 1,023 (831) pence - 'hold'

----------

Citigroup cuts Drax to 'sell' (buy) - price target 437 (474) pence

----------

Barclays cuts Johnson Matthey target to 2,030 (2,100) pence - 'equal weight'

----------

Goldman Sachs cuts ITV to 'sell' (neutral) - price target 60 (67) pence

----------

Jefferies raises Persimmon to 'buy' (hold) - price target 1,706 (1,181) pence

----------

Jefferies cuts Crest Nicholson to 'hold' (buy) - price target 234 (331) pence

----------

Jefferies raises Bellway price target to 3,301 (2,827) pence - 'buy'

----------

Jefferies cuts Moneysupermarket.com to 'hold' (buy) - price target 265 (305) pence

----------

JPMorgan raises Ashmore price target to 185 (183) pence - 'underweight'

----------

SMALL CAP

----------

Numis cuts Wise to 'hold' (buy) - price target 950 pence

----------

Morgan Stanley raises Wise price target to 1,070 (1,050) pence - 'overweight'

----------

Goldman Sachs raises Wise price target to 1,250 (1,200) pence - 'buy'

----------

Goldman Sachs raises Wise price target to 1,250 (1,200) pence - 'buy'

----------

UBS cuts Card Factory price target to 107 (109) pence - 'neutral'

----------

investec cuts Reach to 'hold' (buy) - price target 70 (100) pence

----------

Peel Hunt raises Oxford Nanopore to 'reduce' (sell) - price target 155 pence

----------

Barclays raises Synthomer price target to 416 (187) pence - 'equal weight'

----------

JPMorgan cuts Bank of Ireland to 'underweight' (neutral) - price target 8 (10.80) EUR

----------

JPMorgan cuts AIB price target to 4.80 (5.80) EUR - 'overweight'

----------

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
91011121314151617

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.